Evidence map›Paper›PMID 38253900›Full record

ArticleMolecular biotechnology2024

Circ_0007422 Knockdown Inhibits Tumor Property and Immune Escape of Colorectal Cancer by Decreasing PDL1 Expression in a miR-1256-Dependent Manner.

Dian Yin, Li Yang, Xiu Feng, Xiaolu Zhai, Mei Hua, Jing Liu, Ying Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dian Yin *Department of Oncology, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong City, 226000, Jiangsu, China.
Li Yang *Department of Oncology, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong City, 226000, Jiangsu, China.
Xiu FengDepartment of Oncology, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong City, 226000, Jiangsu, China.
Xiaolu ZhaiDepartment of Oncology, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong City, 226000, Jiangsu, China.
Mei HuaDepartment of Oncology, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong City, 226000, Jiangsu, China.
Jing LiuDepartment of Oncology, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong City, 226000, Jiangsu, China.
Ying ChenDepartment of Oncology, Nantong First People's Hospital, the Second Affiliated Hospital of Nantong University, Nantong City, 226000, Jiangsu, China. zhuishuichen@163.com.ORCID http://orcid.org/0000-0003-3585-1289
Nantong University · CN

Funding

Nantong Municipal Commission of Health and Family Planning QA2021010
6 · The paper itself

Abstract

Circular RNAs (circRNAs) are a group of important molecules involved in the progression of various cancers, including colorectal cancer (CRC). Here, we aim to investigate the role and molecular mechanism of circ_0007422 in regulating CRC malignant progression. The expression levels of circ_0007422, miR-1256, and PDL1 were detected by qRT-PCR. Cell viability, proliferation, apoptosis, invasion, and self-replication ability were analyzed by CCK-8, EdU, flow cytometry, transwell, and spheroid formation experiments, respectively. Protein levels were determined by western blotting assay. CRC cells were co-cultured with CD8 + T cells, phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs), or cytokine-induced killer (CIK) cells in vitro, and CD8 + T-cell apoptosis, IFN-γ and TNF-α levels, and survival rate of CRC cells were analyzed to reveal the role of circ_0007422 in antitumor immunity. The relationship between miR-1256 and circ_0007422 or PDL1 was identified by a dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay. A xenograft tumor model was established to verify the function of circ_0007422 in tumor growth in vivo. Immunohistochemistry (IHC) assay was used to detect positive expression rates of Ki67, E-cadherin, N-cadherin, and PDL1 expression in primary tumors from CRC cells. Circ_0007422 was upregulated in CRC tissues and cells and its knockdown inhibited proliferation, invasion, self-replication ability, and immune escape and promoted apoptosis of CRC cells. Additionally, circ_0007422 bound to miR-1256, which was identified to target PDL1. MiR-1256 inhibition reversed the effects of circ_0007422 knockdown on the tumor properties and immune escape of CRC cells. Moreover, miR-1256 introduction interacted with PDL1 to suppress proliferation, invasion, self-replication ability, and immune escape and promote apoptosis of CRC cells. Further, circ_0007422 knockdown hampered tumorigenesis of CRC cells in vivo. Circ_0007422 knockdown inhibited tumor property and immune escape of colorectal cancer through the miR-1256/PDL1 pathway, providing a potential novel therapeutic target for CRC.

Indexed as

ApoptosisB7-H1 AntigenCell ProliferationColorectal NeoplasmsGene Expression Regulation, NeoplasticMicroRNAsRNA, CircularTumor EscapeAnimalsCell Line, TumorFemaleGene Knockdown TechniquesHumansMaleMiceMice, Inbred BALB CB7-H1 AntigenCD274 protein, humanMicroRNAsRNA, Circularcirc_0007422Colorectal cancermiR-1256PDL1

Identifiers

PMID38253900
OpenAlexW4391097012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.